Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment

Peter F. Lebowitz, Daitoku Sakamuro, George C. Prendergast

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Farnesyl transferase inhibitors (FTIs) are a novel class of antitumor drugs that block the oncogenic activity of Ras. Because FTIs lack significant cell toxicity in vitro and in vivo, a significant question is how they cause tumor regression. We now report that FTIs are in fact potent activators of apoptosis in Ras-transformed cells if attachment to substratum is prevented. When cultured at high density or on polyHEMA, a nonadherent substrate, Ras- transformed cells exhibited massive DNA degradation and cell death within 24 h of treatment with the FTI L-739,749. Death was p53-independent and was inhibited by the apoptosis suppressor BCL-X(L). Furthermore, apoptosis was significantly attenuated by ectopic expression of a farnesyl-independent form of RhoB, a Rho protein previously implicated as a critical target for inhibition by FTIs. The findings suggest a link between FTIs and Rho- dependent adhesion signaling. Furthermore, our work indicates that FTIs revert cells to a state in which cell-substratum attachment is necessary for viability and suggests that apoptosis forms the basis for drug-induced tumor regression.

Original languageEnglish (US)
Pages (from-to)708-713
Number of pages6
JournalCancer Research
Volume57
Issue number4
StatePublished - Mar 3 1997
Externally publishedYes

Fingerprint

Transferases
Apoptosis
L 739749
Antineoplastic Agents
Neoplasms
Cell Death
DNA
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. / Lebowitz, Peter F.; Sakamuro, Daitoku; Prendergast, George C.

In: Cancer Research, Vol. 57, No. 4, 03.03.1997, p. 708-713.

Research output: Contribution to journalArticle

@article{e122ca38164b4af58f73048dd5600217,
title = "Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment",
abstract = "Farnesyl transferase inhibitors (FTIs) are a novel class of antitumor drugs that block the oncogenic activity of Ras. Because FTIs lack significant cell toxicity in vitro and in vivo, a significant question is how they cause tumor regression. We now report that FTIs are in fact potent activators of apoptosis in Ras-transformed cells if attachment to substratum is prevented. When cultured at high density or on polyHEMA, a nonadherent substrate, Ras- transformed cells exhibited massive DNA degradation and cell death within 24 h of treatment with the FTI L-739,749. Death was p53-independent and was inhibited by the apoptosis suppressor BCL-X(L). Furthermore, apoptosis was significantly attenuated by ectopic expression of a farnesyl-independent form of RhoB, a Rho protein previously implicated as a critical target for inhibition by FTIs. The findings suggest a link between FTIs and Rho- dependent adhesion signaling. Furthermore, our work indicates that FTIs revert cells to a state in which cell-substratum attachment is necessary for viability and suggests that apoptosis forms the basis for drug-induced tumor regression.",
author = "Lebowitz, {Peter F.} and Daitoku Sakamuro and Prendergast, {George C.}",
year = "1997",
month = "3",
day = "3",
language = "English (US)",
volume = "57",
pages = "708--713",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment

AU - Lebowitz, Peter F.

AU - Sakamuro, Daitoku

AU - Prendergast, George C.

PY - 1997/3/3

Y1 - 1997/3/3

N2 - Farnesyl transferase inhibitors (FTIs) are a novel class of antitumor drugs that block the oncogenic activity of Ras. Because FTIs lack significant cell toxicity in vitro and in vivo, a significant question is how they cause tumor regression. We now report that FTIs are in fact potent activators of apoptosis in Ras-transformed cells if attachment to substratum is prevented. When cultured at high density or on polyHEMA, a nonadherent substrate, Ras- transformed cells exhibited massive DNA degradation and cell death within 24 h of treatment with the FTI L-739,749. Death was p53-independent and was inhibited by the apoptosis suppressor BCL-X(L). Furthermore, apoptosis was significantly attenuated by ectopic expression of a farnesyl-independent form of RhoB, a Rho protein previously implicated as a critical target for inhibition by FTIs. The findings suggest a link between FTIs and Rho- dependent adhesion signaling. Furthermore, our work indicates that FTIs revert cells to a state in which cell-substratum attachment is necessary for viability and suggests that apoptosis forms the basis for drug-induced tumor regression.

AB - Farnesyl transferase inhibitors (FTIs) are a novel class of antitumor drugs that block the oncogenic activity of Ras. Because FTIs lack significant cell toxicity in vitro and in vivo, a significant question is how they cause tumor regression. We now report that FTIs are in fact potent activators of apoptosis in Ras-transformed cells if attachment to substratum is prevented. When cultured at high density or on polyHEMA, a nonadherent substrate, Ras- transformed cells exhibited massive DNA degradation and cell death within 24 h of treatment with the FTI L-739,749. Death was p53-independent and was inhibited by the apoptosis suppressor BCL-X(L). Furthermore, apoptosis was significantly attenuated by ectopic expression of a farnesyl-independent form of RhoB, a Rho protein previously implicated as a critical target for inhibition by FTIs. The findings suggest a link between FTIs and Rho- dependent adhesion signaling. Furthermore, our work indicates that FTIs revert cells to a state in which cell-substratum attachment is necessary for viability and suggests that apoptosis forms the basis for drug-induced tumor regression.

UR - http://www.scopus.com/inward/record.url?scp=0031050738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031050738&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 708

EP - 713

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -